Related Experiment Videos
Oral chemotherapy: rationale and future directions
1Department of Medicine, Cancer Research Center, University of Chicago, IL, USA.
Summary
Oral chemotherapy offers convenience and cost benefits but faces challenges in bioavailability and patient adherence. Innovations in drug metabolism inhibition are key to overcoming these limitations for effective cancer treatment.
Area of Science:
- Oncology
- Pharmacology
- Drug Development
Background:
- Oral chemotherapy is expanding due to pharmacoeconomic factors and patient preference.
- Challenges include patient compliance and bioavailability limitations for oral administration.
- Oral formulations are increasingly important for novel therapies requiring long administration periods.
Purpose of the Study:
- To discuss pharmacoeconomic principles driving oral chemotherapy formulation.
- To identify patient preference as a key factor in oral drug design.
- To analyze bioavailability limitations and patient compliance issues with oral chemotherapy.
Main Methods:
- Review of pharmacokinetic literature for orally formulated cancer agents.
- Comparison of pharmacokinetic data for various oral chemotherapy drugs.
- Discussion of novel oral cytotoxics and modulators.
Main Results:
- Significant variability in bioavailability observed for many oral cancer chemotherapeutics.
- Narrow therapeutic index in cancer chemotherapy amplifies bioavailability concerns.
- Improved bioavailability and reduced interpatient variability are crucial for new formulations.
Conclusions:
- Oral chemotherapy is transforming oncology practice, driven by cost, convenience, and quality of life.
- Overcoming bioavailability and compliance issues is essential for efficacy, especially in adjuvant settings.
- Inhibitors of CYP3A4, P-glycoprotein (P-gp), and dihydropyrimidine dehydrogenase are vital for successful oral chemotherapy development.